The Goldman Sachs Group Issues Pessimistic Forecast for Insulet (NASDAQ:PODD) Stock Price

Key Points

• The Goldman Sachs Group cut its price target on Insulet to $277 from $326 but kept a buy rating, a level that implies roughly a 36.8% upside from the stock's recent close.
• Analyst sentiment remains broadly positive with a consensus of "Moderate Buy"—19 Buys, 4 Holds and 1 Sell—and an average price target of $342.
• Insulet recently beat estimates with $1.55 EPS (vs. $1.48) and $783.8M revenue (vs. $768.3M), with quarterly revenue up 31.2% year‑over‑year.

Insulet (NASDAQ:PODD - Get Free Report) had its target price lowered by equities researchers at The Goldman Sachs Group from $326.00 to $277.00 in a report released on Wednesday,MarketScreener reports. The firm presently has a "buy" rating on the medical instruments supplier's stock. The Goldman Sachs Group's price objective indicates a potential upside of 36.82% from the company's previous close.

A number of other research analysts also recently commented on PODD. Oppenheimer lowered their price objective on Insulet from $365.00 to $300.00 and set an "outperform" rating for the company in a research note on Thursday, February 19th. BTIG Research reiterated a "buy" rating and issued a $380.00 target price on shares of Insulet in a research note on Wednesday, February 18th. UBS Group reissued a "buy" rating on shares of Insulet in a report on Thursday, December 18th. Stifel Nicolaus lowered their price target on shares of Insulet from $370.00 to $350.00 and set a "buy" rating for the company in a research report on Wednesday, February 4th. Finally, Sanford C. Bernstein cut their price objective on shares of Insulet from $380.00 to $330.00 and set an "outperform" rating on the stock in a research report on Thursday, February 19th. Nineteen equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $342.00.

Insulet Stock Down 0.5%

Shares of NASDAQ:PODD opened at $202.46 on Wednesday. The stock has a market capitalization of $14.25 billion, a price-to-earnings ratio of 57.85, a price-to-earnings-growth ratio of 1.22 and a beta of 1.47. Insulet has a 1-year low of $198.10 and a 1-year high of $354.88. The company's fifty day moving average is $235.63 and its two-hundred day moving average is $281.99. The company has a debt-to-equity ratio of 0.61, a quick ratio of 2.15 and a current ratio of 2.81.

Insulet (NASDAQ:PODD - Get Free Report) last issued its earnings results on Wednesday, February 18th. The medical instruments supplier reported $1.55 EPS for the quarter, beating analysts' consensus estimates of $1.48 by $0.07. The company had revenue of $783.80 million during the quarter, compared to the consensus estimate of $768.31 million. Insulet had a return on equity of 24.90% and a net margin of 9.12%.Insulet's quarterly revenue was up 31.2% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.15 earnings per share. Equities analysts anticipate that Insulet will post 3.92 EPS for the current year.

Insider Buying and Selling at Insulet

In other Insulet news, Director Michael R. Minogue purchased 2,030 shares of the company's stock in a transaction that occurred on Wednesday, February 25th. The shares were purchased at an average cost of $246.23 per share, with a total value of $499,846.90. Following the completion of the transaction, the director owned 17,483 shares of the company's stock, valued at approximately $4,304,839.09. This represents a 13.14% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 0.39% of the company's stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Larson Financial Group LLC lifted its holdings in Insulet by 114.6% in the 4th quarter. Larson Financial Group LLC now owns 88 shares of the medical instruments supplier's stock worth $25,000 after purchasing an additional 47 shares during the last quarter. University of Texas Texas AM Investment Management Co. acquired a new position in shares of Insulet during the fourth quarter worth approximately $26,000. Elyxium Wealth LLC bought a new stake in shares of Insulet in the fourth quarter valued at approximately $28,000. DV Equities LLC acquired a new stake in shares of Insulet in the fourth quarter worth $28,000. Finally, MV Capital Management Inc. acquired a new stake in shares of Insulet in the fourth quarter worth $29,000.

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company's core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet's products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company's product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.